Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
about
Bortezomib for the treatment of multiple myelomaIncidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysisReview of health-related quality of life data in multiple myeloma patients treated with novel agents.Bortezomib in multiple myeloma: systematic review and clinical considerations.Sleep disruption in hematopoietic cell transplantation recipients: prevalence, severity, and clinical managementMyelomatous pleural effusion involvement in 23 patients with multiple myeloma: A single-center clinical analysisSalvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trialGuidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2012The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials.Bortezomib-induced peripheral neurotoxicity: an update.Optimizing quality of life in multiple myeloma patients: current options, challenges and recommendations.The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma.A systematic review of health-related quality of life in longitudinal studies of myeloma patients.Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma.The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma.Treatment options for refractory/relapsed multiple myeloma: an updated evidence synthesis by network meta-analysis
P2860
Q24185881-97B6A6B5-7C30-42B8-9979-649C0713E9ABQ26991817-F18DE995-32D5-490A-9C46-8A7338CA313DQ30650394-D08FF593-B06D-48BE-B4AB-AD1C095F57B7Q33982728-7B1A275A-E8C3-4575-8772-417C8CD4C4E5Q34175300-8558DAD4-E1CA-477B-839C-DA4AB5D7CFCBQ35663458-3CE10AE7-ED53-47BF-951C-98DD0D25A846Q36138646-A9697836-87B7-4E2A-9AEC-A192E527A3CBQ37057028-BE4C13C1-35C4-4CFF-89D3-FACFBDE6099CQ37384918-E4F04427-38D1-48E5-90C0-E0675CED1095Q38234733-EDA62015-E7F7-4382-B3A6-D565D6793AD9Q38367654-2952684A-2F01-45EC-8339-D4AC54845A16Q38685108-E4130E64-6CBF-401D-877B-6F0749A9895AQ38742505-39869B29-B470-4DB8-8748-BE711FEB355DQ48139344-B428582F-5277-40D5-A3CF-1DD10EF954E1Q52686509-7D84A249-65E9-410F-A198-C9D7E0375883Q55513961-F537951B-C04F-43D3-B517-0E378BB81E12Q58729834-B0C44222-1ACD-4DF9-A725-F497A1AD0530
P2860
Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Thalidomide and dexamethasone ...... ry myeloma: a randomized study
@ast
Thalidomide and dexamethasone ...... ry myeloma: a randomized study
@en
type
label
Thalidomide and dexamethasone ...... ry myeloma: a randomized study
@ast
Thalidomide and dexamethasone ...... ry myeloma: a randomized study
@en
prefLabel
Thalidomide and dexamethasone ...... ry myeloma: a randomized study
@ast
Thalidomide and dexamethasone ...... ry myeloma: a randomized study
@en
P2093
P2860
P50
P1476
Thalidomide and dexamethasone ...... ry myeloma: a randomized study
@en
P2093
Agneta Swedin
Annika Othzén
Björn Andréasson
Karin Forsberg
Kristina Carlson
Lene Meldgaard Knudsen
Margaretha S Carlsson
Martin Hjorth
Max Flogegård
Niels Frost Andersen
P2860
P304
P356
10.1111/J.1600-0609.2012.01775.X
P577
2012-03-30T00:00:00Z